ArticleJournal of translational medicine2025
ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells.Discover oncology · 2026Article
- Article
- Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoplasmic reticulum oxidoreductase 1 A (ERO1A) is a protein disulfide oxidoreductase. ERO1A is involved in the progression of various tumors, but the potential mechanism of its action in bladder cancer remains unclear.
methodsIn this study, we utilized data from public databases to investigate the expression pattern of ERO1A. Through CCK-8, EdU, wound healing, and Transwell invasion assays, we evaluated the effects of ERO1A on the proliferation, migration, and invasion abilities of bladder cancer cells. We further explored the specific molecular mechanism of ERO1A. Finally, a subcutaneous tumor formation model in nude mice was established to detect the function of ERO1A in vivo.
resultsSilencing the expression of ERO1A inhibits the proliferation, migration and invasion of bladder cancer cells, and also suppresses tumor growth in vivo. Mechanistically, ERO1A binds to and suppresses the phosphorylation of ALOX5, which in turn activates the JAK-STAT signaling pathway and subsequently suppresses autophagy.
conclusionIn conclusion, this study demonstrates that ERO1A could promote the proliferation, migration, and invasion of bladder cancer cells by regulating the ALOX5/JAK/STAT/autophagy signaling axis. ERO1A may serve as a novel molecular marker for the diagnosis and treatment of clinical bladder cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.